دورية أكاديمية
أعرض في EDS

Anti-Obesity Therapeutic Targets Studied In Silico and In Vivo: A Systematic Review.

التفاصيل البيبلوغرافية
العنوان: Anti-Obesity Therapeutic Targets Studied In Silico and In Vivo: A Systematic Review.
المؤلفون: de Medeiros WF; Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil., Gomes AFT; Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil., Aguiar AJFC; Biochemistry and Molecular Biology Postgraduate Program, Biosciences Center, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil., de Queiroz JLC; Biochemistry and Molecular Biology Postgraduate Program, Biosciences Center, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil., Bezerra IWL; Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil.; Department of Nutrition, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil., da Silva-Maia JK; Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil.; Department of Nutrition, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil., Piuvezam G; Public Health Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-400, Brazil.; Public Health Department, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil., Morais AHA; Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil.; Biochemistry and Molecular Biology Postgraduate Program, Biosciences Center, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.; Department of Nutrition, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 25; Vol. 25 (9). Date of Electronic Publication: 2024 Apr 25.
نوع المنشور: Journal Article; Systematic Review; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Obesity*/drug therapy , Obesity*/metabolism , Computer Simulation*, Humans ; Animals ; Molecular Docking Simulation ; Anti-Obesity Agents/pharmacology ; Anti-Obesity Agents/therapeutic use ; Lipase/metabolism ; Lipase/antagonists & inhibitors ; Molecular Targeted Therapy/methods
مستخلص: In the age of information technology and the additional computational search tools and software available, this systematic review aimed to identify potential therapeutic targets for obesity, evaluated in silico and subsequently validated in vivo. The systematic review was initially guided by the research question "What therapeutic targets have been used in in silico analysis for the treatment of obesity?" and structured based on the acronym PECo (P, problem; E, exposure; Co, context). The systematic review protocol was formulated and registered in PROSPERO (CRD42022353808) in accordance with the Preferred Reporting Items Checklist for Systematic Review and Meta-Analysis Protocols (PRISMA-P), and the PRISMA was followed for the systematic review. The studies were selected according to the eligibility criteria, aligned with PECo, in the following databases: PubMed, ScienceDirect, Scopus, Web of Science, BVS, and EMBASE. The search strategy yielded 1142 articles, from which, based on the evaluation criteria, 12 were included in the systematic review. Only seven these articles allowed the identification of both in silico and in vivo reassessed therapeutic targets. Among these targets, five were exclusively experimental, one was exclusively theoretical, and one of the targets presented an experimental portion and a portion obtained by modeling. The predominant methodology used was molecular docking and the most studied target was Human Pancreatic Lipase (HPL) (n = 4). The lack of methodological details resulted in more than 50% of the papers being categorized with an "unclear risk of bias" across eight out of the eleven evaluated criteria. From the current systematic review, it seems evident that integrating in silico methodologies into studies of potential drug targets for the exploration of new therapeutic agents provides an important tool, given the ongoing challenges in controlling obesity.
References: Protein Sci. 2022 Jan;31(1):187-208. (PMID: 34676613)
Sci Transl Med. 2019 Apr 17;11(488):. (PMID: 30996080)
Obes Rev. 2020 Dec;21(12):e13081. (PMID: 32691524)
PLoS One. 2020 Jan 13;15(1):e0227637. (PMID: 31929574)
J Biol Chem. 2008 May 9;283(19):12949-59. (PMID: 18321850)
Maedica (Bucur). 2021 Sep;16(3):445-452. (PMID: 34925601)
Am J Cardiovasc Drugs. 2019 Aug;19(4):349-364. (PMID: 30793263)
Molecules. 2015 Jul 22;20(7):13384-421. (PMID: 26205061)
CMAJ. 2020 Aug 4;192(31):E875-E891. (PMID: 32753461)
Structure. 2019 Feb 5;27(2):211-217. (PMID: 30595456)
J Physiol. 2006 Jul 1;574(Pt 1):55-62. (PMID: 16709632)
Future Med Chem. 2020 Mar;12(6):533-561. (PMID: 32048880)
Foods. 2020 Sep 25;9(10):. (PMID: 32992701)
Food Chem. 2023 Mar 30;405(Pt A):134824. (PMID: 36370554)
Altern Lab Anim. 2020 Jul;48(4):146-172. (PMID: 33119417)
Chem Senses. 2016 Feb;41(2):169-76. (PMID: 26671250)
Mol Metab. 2017 Oct;6(10):1113-1125. (PMID: 29031713)
Pharmaceuticals (Basel). 2022 Jul 14;15(7):. (PMID: 35890163)
Nat Rev Drug Discov. 2022 Mar;21(3):201-223. (PMID: 34815532)
Arq Bras Cardiol. 2021 Mar;116(3):516-658. (PMID: 33909761)
Nature. 2004 Apr 1;428(6982):569-74. (PMID: 15058305)
Front Chem. 2020 Apr 28;8:343. (PMID: 32411671)
Biomolecules. 2021 Jul 16;11(7):. (PMID: 34356668)
Nature. 2002 Jan 17;415(6869):339-43. (PMID: 11797013)
PLoS One. 2022 Dec 12;17(12):e0279039. (PMID: 36508447)
J Med Chem. 2008 Nov 27;51(22):7216-33. (PMID: 18954042)
Lancet. 2007 Nov 17;370(9600):1706-13. (PMID: 18022033)
EMBO Rep. 2021 Nov 4;22(11):e52348. (PMID: 34569703)
Int J Mol Sci. 2019 Jun 06;20(11):. (PMID: 31174387)
J Adv Vet Anim Res. 2019 Dec 14;7(1):103-114. (PMID: 32219116)
SAGE Open Med. 2020 Apr 28;8:2050312120918265. (PMID: 32435480)
Front Physiol. 2019 Jun 11;10:704. (PMID: 31281260)
J Lipid Res. 2009 Apr;50 Suppl:S138-43. (PMID: 19047759)
PLoS One. 2013 Nov 26;8(11):e80339. (PMID: 24303008)
J Cardiovasc Thorac Res. 2019;11(4):254-263. (PMID: 31824606)
Pharmaceuticals (Basel). 2023 Jan 28;16(2):. (PMID: 37259340)
Molecules. 2021 Oct 13;26(20):. (PMID: 34684760)
J Chem Inf Model. 2021 Nov 22;61(11):5362-5376. (PMID: 34652141)
Pharmaceuticals (Basel). 2022 May 23;15(5):. (PMID: 35631472)
Nat Rev Mol Cell Biol. 2017 Jan;18(1):31-42. (PMID: 27808276)
J Exp Med. 1997 Aug 29;186(5):683-93. (PMID: 9271584)
Int J Mol Sci. 2022 May 27;23(11):. (PMID: 35682702)
Diabetol Metab Syndr. 2021 Mar 18;13(1):32. (PMID: 33736684)
Genes Dis. 2021 Jan 28;9(1):51-61. (PMID: 35005107)
Hepatology. 2019 Apr;69(4):1535-1548. (PMID: 30506571)
J Lipid Res. 2006 Feb;47(2):412-20. (PMID: 16304351)
Pharmacol Ther. 2020 Apr;208:107477. (PMID: 31926199)
Acta Pharm Sin B. 2022 Jul;12(7):3049-3062. (PMID: 35865092)
Nat Chem Biol. 2011 Oct 16;7(12):885-7. (PMID: 22002720)
Nat Genet. 2010 Dec;42(12):1086-92. (PMID: 21076408)
J Endocrinol. 2019 Jun 1;241(3):R81-R96. (PMID: 30959481)
QRB Discov. 2022 Sep 01;3:e14. (PMID: 37529294)
Eur J Pharmacol. 2022 Jan 15;915:174611. (PMID: 34798121)
Phytomedicine. 2011 Jun 15;18(8-9):795-801. (PMID: 21315569)
BMC Biotechnol. 2020 Oct 2;20(1):52. (PMID: 33008398)
J Diabetes Metab Disord. 2020 Mar 12;19(1):197-204. (PMID: 32420297)
Metabolism. 2019 Mar;92:121-135. (PMID: 30445141)
Obes Pillars. 2022 Apr 15;2:100018. (PMID: 37990711)
Drug Discov Today. 2005 May 15;10(10):693-702. (PMID: 15896682)
Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275)
Biology (Basel). 2022 Jul 11;11(7):. (PMID: 36101419)
Endocrinology. 2013 Sep;154(9):3130-40. (PMID: 23751875)
Food Res Int. 2022 Sep;159:111619. (PMID: 35940810)
Prev Nutr Food Sci. 2017 Dec;22(4):251-262. (PMID: 29333376)
J Biomol Struct Dyn. 2023 Jul;41(11):4863-4872. (PMID: 35575483)
J Mol Endocrinol. 2005 Apr;34(2):339-51. (PMID: 15821101)
Bioorg Chem. 2019 May;86:322-338. (PMID: 30743173)
Cell Mol Gastroenterol Hepatol. 2023;15(3):633-663. (PMID: 36410709)
J Biol Chem. 1997 Apr 18;272(16):10669-77. (PMID: 9099716)
Int J Obes (Lond). 2020 Nov;44(11):2179-2193. (PMID: 32317751)
معلومات مُعتمدة: 303094/2022-2 National Council for Scientific and Technological Development; 001 Coordenação de Aperfeicoamento de Pessoal de Nível Superior
فهرسة مساهمة: Keywords: computer simulation; molecular conformation; molecular docking simulation; molecular dynamics simulation; obesity; peptides
المشرفين على المادة: 0 (Anti-Obesity Agents)
EC 3.1.1.3 (Lipase)
تواريخ الأحداث: Date Created: 20240511 Date Completed: 20240511 Latest Revision: 20240607
رمز التحديث: 20240608
مُعرف محوري في PubMed: PMC11083175
DOI: 10.3390/ijms25094699
PMID: 38731918
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25094699